Title |
Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia
|
---|---|
Published in |
Drugs, January 2015
|
DOI | 10.1007/s40265-014-0344-z |
Pubmed ID | |
Authors |
Gillian M. Keating |
Abstract |
Silodosin is a highly selective α1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Oral silodosin had a rapid onset of effect in men with lower urinary tract symptoms (LUTS) associated with BPH, with improvements seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life in well-designed, 12-week trials. Silodosin was noninferior to tamsulosin in terms of improving LUTS associated with BPH. The efficacy of silodosin was maintained in 9-month extension studies and was also seen in a phase IV study conducted in a real-world setting. Silodosin was generally well tolerated and was associated with a low risk of orthostatic hypotension. Abnormal ejaculation was the most commonly reported adverse event, although few patients discontinued treatment with silodosin because of this adverse event. In conclusion, silodosin is a useful option for the treatment of LUTS associated with BPH. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 20% |
Other | 3 | 15% |
Student > Bachelor | 3 | 15% |
Student > Postgraduate | 2 | 10% |
Student > Master | 2 | 10% |
Other | 3 | 15% |
Unknown | 3 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 35% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
Nursing and Health Professions | 2 | 10% |
Biochemistry, Genetics and Molecular Biology | 2 | 10% |
Agricultural and Biological Sciences | 1 | 5% |
Other | 1 | 5% |
Unknown | 5 | 25% |